Aller au contenu principal
Profil bibliographique

Martin Ojok

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

4Publications signalées
86Citations signalées
1Affiliations récentes

Les institutions déclarées

Les domaines associés

HIV/AIDS drug development and treatmentHIV/AIDS Research and InterventionsHIV-related health complications and treatmentsTuberculosis Research and EpidemiologyHIV Research and Treatment

Les publications récentes

Accès ouvert 2023 article OpenAlex

Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis of the ODYSSEY trial

Anna Turkova, Ellen White, Adeodata Kekitiinwa, Vivian Mumbiro et autres

BACKGROUND: Cohort studies in adults with HIV showed that dolutegravir was associated with neuropsychiatric adverse events and sleep problems, yet data are scarce in children and adolescents. We aimed to evaluate neuropsychiatric manifestations in children and adolescents treated with dolutegravir-based treatment versus …

gb, Ouganda, Zimbabwe, Afrique du Sud, th, de, es, fr, it (code pays fourni par la source)

12 citations The Lancet Child & Adolescent Health
Accès ouvert 2023 article OpenAlex

Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial

Alexandra Compagnucci, Man Kam Chan, Yacine Saïdi, Tim Roy Cressey et autres

Background Integrase inhibitor (INSTI) with boosted darunavir (DRV/r), a regimen with a high-resistance barrier, avoiding NRTI toxicities, might be a switching option in children living with HIV (CLWHIV). Methods SMILE is a randomised non-inferiority trial evaluating safety and antiviral efficacy of once-daily …

fr, gb, th, it, Ouganda, Afrique du Sud, ua, ar, pa, mx, es, ch, pt, de (code pays fourni par la source)

16 citations EClinicalMedicine
Accès ouvert 2022 article OpenAlex

Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial

Pauline Mary Amuge, Abbas Lugemwa, Ben Wynne, Hilda Angela Mujuru et autres

BACKGROUND: Young children living with HIV have few treatment options. We aimed to assess the efficacy and safety of dolutegravir-based antiretroviral therapy (ART) in children weighing between 3 kg and less than 14 kg. METHODS: ODYSSEY is an open-label, randomised, non-inferiority trial …

Ouganda, gb, Zimbabwe, Afrique du Sud, it, es (code pays fourni par la source)

34 citations The Lancet HIV
Accès ouvert 2022 article OpenAlex

Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial

Anna Turkova, Hylke Waalewijn, Man Kam Chan, Pauline Bollen et autres

BACKGROUND: Children with HIV-associated tuberculosis (TB) have few antiretroviral therapy (ART) options. We aimed to evaluate the safety and pharmacokinetics of dolutegravir twice-daily dosing in children receiving rifampicin for HIV-associated TB. METHODS: on the first substudy day. All children within ODYSSEY with …

gb, nl, Zimbabwe, Ouganda, Afrique du Sud, th, us (code pays fourni par la source)

24 citations The Lancet HIV

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.